OTCMKTS:NRXGQ NephroGenex (NRXGQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About NephroGenex Stock (OTCMKTS:NRXGQ) 30 days 90 days 365 days Advanced Chart Get NephroGenex alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2,000 shsAverage Volume26,223 shsMarket Capitalization$36 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.Read More… Receive NRXGQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NephroGenex and its competitors with MarketBeat's FREE daily newsletter. Email Address NRXGQ Stock News HeadlinesHabib Kairouz's Net WorthAugust 24, 2024 | benzinga.comElicera Therapeutics AB (ELIC)August 24, 2023 | investing.comElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of the 10 worst business ideas ever.” Founder Peter Thiel saw 227,490% returns in one year. Tesla was dismissed as “a rich man’s toy.” Now it's worth more than the next 40 car companies combined.June 18, 2025 | The Oxford Club (Ad)LL Lucky Games publ AB (LADYLU)August 17, 2023 | investing.comXinjiang Daqo New Energy Co Ltd (688303)July 13, 2023 | investing.comTsukuba Bank Ltd (8338)July 12, 2023 | investing.comPEXA Group Ltd (PXA)July 11, 2023 | investing.comKosei Securities Co Ltd (8617)June 21, 2023 | investing.comSee More Headlines NRXGQ Stock Analysis - Frequently Asked Questions How do I buy shares of NephroGenex? Shares of NRXGQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorManufacturing Industry Electronic Computer Manufacturing Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NRXGQ Previous SymbolNASDAQ:NRX CIK1338095 Webwww.nephrogenex.com Phone+1-609-5538887FaxN/AEmployees1,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,950,000Free FloatN/AMarket Cap$36 thousand OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:NRXGQ) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NephroGenex, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share NephroGenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.